Multifunctional nanoparticle compositions and uses thereof
Disclosed herein are multifunctional nanoparticle compositions. The compositions can be useful for the treatment of cancer by enhancing the anti-tumor effectiveness of radiation directed to a tissue, cell or a tumor and the methods of use thereof. The multifunctional nanoparticle composition comprises a metal oxide nanoparticle core; a functional coating on the surface of the metal oxide nanoparticle core; and a matrix carrier in which the coated nanoparticle is embedded.
1. A method of enhancing a radiation directed to a tissue or a tumor in a subject comprising the steps of:
(a) reducing hypoxia in the tissue or tumor by producing oxygen in the tissue or tumor by administering an amount of a multifunctional nanoparticle composition to the subject, the multifunctional nanoparticle composition comprising a matrix having multiple coated nanoparticles that react with H 2 O 2 present in the tissue or tumor to produce O 2 in the tissue or tumor, each coated nanoparticle comprising a metal oxide nanoparticle precursor stabilized by a positively charged polyelectrolyte, and a functional coating on a surface of the metal oxide nanoparticle precursor, and
(b) applying radiation to the subject,
wherein the production of oxygen in the tissue or tumor combines with the radiation to make DNA damage in the tissue or tumor permanent thereby the radiation is enhanced in the subject.
2. The method of claim 1 , wherein the matrix is selected from the group consisting of organic groups, inorganic compounds, proteins, nucleic acids, polymers, lipids and mixtures thereof.
3. The method of claim 1 , wherein each coated nanoparticle further comprises a functional moiety, the functional moiety being selected from the group consisting of a targeting moiety, a detectable moiety, a radioisotope, a radionuclide and mixtures thereof.
4. The method of claim 1 , wherein each metal oxide nanoparticle is a manganese dioxide nanoparticle.
5. The method of claim 1 , wherein the positively charged electrolyte is poly(allylamine hydrochloride) (PAH).
6. The method of claim 5 , wherein the matrix comprises albumin, a graft terpolymer (TER), a polyoxyethylene stearate (lipid-PEG), a lipid or a grafted amphiphilic polymer (PMA).
7. The method of claim 6 , wherein:
(a) the matrix comprises the albumin, the coated nanoparticles are manganese dioxide nanoparticles (MD NP) and the multifunctional nanoparticle composition is albumin-MD NP; or
(b) the matrix comprises the TER, and the multifunctional nanoparticle composition is TER-MD NP; or
(c) the matrix comprises the lipid-PEG having a chain of about 2 kDa to about 10 kDa, and wherein the multifunctional nanoparticle composition is a PEG-TER-MD NP; or
(d) the matrix comprises the lipid, and the lipid matrix comprises a myristic acid and a lipid-PEG, and wherein the multifunctional nanoparticle composition is lipid-MD NP; or
(e) the matrix comprises the PMA, the PMA is a poly(isobutylene-alt-maleic anhydride-hexadeylamine), and wherein the multifunctional nanoparticle composition is PMA-MD NP.
8. The method of claim 7 , wherein the albumin-MD NP is about 20 nm to about 1000 nm in diameter, the TER-MD NP is about 50 nm to about 1000 nm in diameter, the PEG-TER-MD NP is about 50 nm to about 1000 nm in diameter, L-MD NP is about 50 nm to about 1000 nm in diameter and the PMA-MD NP is about 50 nm to about 1000 nm in diameter.
9. The method of claim 1 , wherein the multifunctional nanoparticle composition is negatively charged.
10. The method of claim 1 , wherein each coated nanoparticle embedded in the matrix has a mean particle size of 10 nm to 1000 nm.
11. The method of claim 1 , wherein the metal oxide is selected from the group consisting of MnO 2 , Mn 2 O 3 , Mn 2 O 7 , MnOOH, Mn 3 O 4 , Mn(C 2 O 4 ), MgO, NiO 2 , Co 3 O 4 , AgO, CuO, BiO, Rb 2 O, In 2 O, Tl 2 O 3 , Cs 2 O, and HfO 2 .
12. The method of claim 1 , wherein the administration is intratumoral, peritumoral, or intravenous injection.
13. The method of claim 1 , wherein the step of administering the composition is prior to the step of applying the radiation.
14. The method of claim 1 , wherein the composition is intravenously injected to the subject about 1 to about 24 hours prior to the radiation.
15. The method of claim 1 , wherein the composition is intratumorally injected to the subject about 5 minutes to about 3 hours prior to the radiation.
16. The method of claim 1 , wherein the method is for treating a cancer in the subject.